An interventional study of Transcranial photobiomodulation (tPBM) - Mobile System in ALL, Hodgkin Lymphoma and Cancer, sponsored by St. Jude Children's Research Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Device feasibility
Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning.
Primary Objective
To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive performance in survivors of ALL and HL.
Secondary Objectives
To estimate the potential efficacy of alpha and gamma frequency tPBM on cognitive performance in survivors of ALL and HL.
Exploratory Objectives
To estimate the effects of home-based tPBM paired with remote cognitive training on patient reported symptoms of executive dysfunction, sleep, depression, anxiety, fatigue, and pain in survivors of ALL and HL.
Survivors with ALL and HL with identified executive function impairment will be randomized to receive stimulation with alpha tPBM + cognitive training, gamma tPBM + cognitive training or sham tPBM + cognitive training three days per week for a 2-month intervention period The tPBM will be applied to nodes in the default mode network.
885 studies on the registry are indexed under Hodgkin Disease; 132 are open to participants now.
This study's enrollment of 44 is close to the median of 44 across 726 interventional studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →St. Jude Children's Research Hospital is the lead sponsor of 434 studies on the registry; 99 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 35 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
three days per week for a 2-month intervention period (5 ALL and 5 HL)
Device: Transcranial photobiomodulation (tPBM) - Mobile System
three days per week for a 2-month intervention period (5 ALL and 5 HL)
Device: Transcranial photobiomodulation (tPBM) - Mobile System
Sham stimulations will act as the control for this study three days per week for a 2-month intervention period (5 ALL and 5 HL)
Device: Transcranial photobiomodulation (tPBM) - Mobile System
The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Also known as: Vielight portable tPBM NeURO device.
Number of participants who completed a two-month trial of paired photobiomodulation (PBM) therapy and cognitive training
The trial will be considered feasible if at least 15 of 30 survivors are able to complete 18 of 24 sessions (PBM along with cognitive training).
Time frame: 4 months after participant enrollment
CNS Vital Signs adaptions of the Rey auditory verbal learning test (RVLT).
RVLT is a test that evaluate working memory.
Time frame: 2 month and 4 months after enrollment
CNS Vital Signs adaptions of the Rey visual design learning (RVDL) test.
RVDL is a test that evaluate working memory.
Time frame: 2 month and 4 months after enrollment
CNS Vital Signs implemented Stroop color and word test.
The Stroop test is a test that evaluates Inhibitory control.
Time frame: 2 month and 4 months after enrollment
CNS Vital Signs implemented Shifting Attention Test.
The Shifting attention test and Stroop test are tests that are used to measure cognitive flexibility.
Time frame: 2 month and 4 months after enrollment
CNS Vital Signs implementation of the Continuous Performance Test (CPT).
The CPT test is a test that evaluates attention.
Time frame: 2 month and 4 months after enrollment
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital